Investigational drug · Phase 2
SPGL008
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for NMIBC, Non Small Cell Lung Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "SPGL008"
First trial start
2026
Mar 12, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SPGL008", any sponsor or status.
Conditions studied
As listed on its trial records.
- NMIBC
- Non Small Cell Lung Cancer
Approved drugs for the same conditions: Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "SPGL008" as an intervention, largest first.
- SPGL008 in Combination With SSGJ-706 ± Chemotherapy for Advanced Non-small Cell Lung CancerNot yet recruiting
Shenyang Sunshine Pharmaceutical Co., LTD.Industry
NCT07874984 · 220 participants (planned) · Start Nov 2026 · Primary completion Nov 2027
Drug: SSGJ-706; SPGL008 and 1 more · For: Non Small Cell Lung Cancer
Shenyang Sunshine Pharmaceutical Co., LTD.Industry
NCT07445308 · 120 participants (planned) · Start Mar 12, 2026 · Primary completion Nov 21, 2028
Drug: SPGL008 · For: NMIBC
Shenyang Sunshine Pharmaceutical Co., LTD.Industry
NCT07038005 · 96 participants (planned) · Start Jul 30, 2025 · Primary completion Sep 22, 2026
Drug: SPGL008 · For: Advanced Malignant Tumors
Sites: Chongqing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for NMIBC
- BCGPhase 38 trials
ImmunityBio, Inc. · Non-muscle Invasive Bladder Cancer (NMIBC), Papillary-Only Non-muscle-invasive Bladder Cancer, Tuberculosis
- SHR-1501Phase 34 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Papillary-Only Non-muscle-invasive Bladder Cancer, Patients With Advanced or Metastatic Malignant Tumors, NMIBC
- Pirarubicin HydrochloridePhase 31 trial
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NMIBC
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.